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Since their first isolation and characterization by Friedenstein
et al. in 1974 [1], mesenchymal stem cells (MSCs) were
proven essential for tissue regeneration and homeostasis.
Over the years, thanks to a better understanding of the
molecular mechanisms underlying the therapeutic effects of
MSCs, several approaches with MSC-based therapies have
been proposed, in order to treat different human diseases [2].
In this light, MSCs are currently being tested in preclini-
cal in vivo settings as well as in early-stage clinical trials for
their ability to modulate immune responses, fostering wound
healing and tissue regeneration of various tissue types and
organs, including the skin, bone, cartilage, brain, muscle,
and tendons [3].
As defined by the International Society for Cellular
Therapy (ISCT) in 2006, culture-expanded MSCs [4], har-
vested from bone marrow, adipose tissue, umbilical cord,
dental tissues, and other sources, are being studied in clinical
trials across evidence-based practice and numerous regula-
tory jurisdictions worldwide [5–9].
Recent reports have demonstrated therapeutic effects by
MSCs on animal models, explained by the ability of MSCs
to be activated by signals from injured tissues: in these dam-
aged areas, MSCs showed regenerative behaviour, with the
promotion of the tissue healing, and paracrine activities, with
the secretion of anti-inflammatory factors [10].
Experimental in vivo models showed that the direct
administrationof the same factors secretedbyMSCsreplicated
the local anti-inflammatory effects, highlighting the double
role of MSCs as players of tissue regeneration and as reg-
ulators of the local environment in many pathological
conditions [10–12].
Actually, several clinical trials focused on the role of
MSCs in the treatment of the autoimmunity are currently in
progress, with the aim to verify new therapeutic approaches
for the most common and severe diseases, such as Crohn’s
disease, type 1 diabetes, and systemic lupus erythematosus
(see www.clinicaltrials.gov) [10, 11].
Despite the numerous barriers to their clinical use, MSCs
have shown sufficient promise to garner a primary place in
the field of regenerative medicine. MSC-based cell thera-
pies have significant implications for human health: clini-
cal studies are greatly needed to confirm or to stimulate
the basic and translational researches aimed to reach
cutting-edge results.
The key deliverable for the scientific community involved
in developing MSC clinical applications could be to better
understand the mechanisms underlying the MSC commit-
ment and behaviour, by creation of MSC-based platforms
which could provide a useful guidance on selection of proper
clinical trial subjects based on hypothesis-driven mechanistic
predictors of response [13].
Although all are such promising results, there are still
severe limitations that currently delay the implementation
of stem cell models in practice assays. The articles published
in this special issue make use of MSC application for transla-
tional regenerative medicine and try to address some of these
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limitations. The original research articles as well as the review
articles collected in this special issue will support the research
community in approaching the goal of obtaining models for
the lab that can better mimic the in vivo conditions.
Various methodologies have been employed to improve
the cell phenotype generated from MSCs, for example, by
modulation of biochemical activity, creation of scaffolds,
and addition of growth factors to the culture medium. Fur-
thermore, several topics regarding molecular mechanisms
controlling MSC differentiation are covered.
Significant findings have been made in clinical research
on application of MSCs for translational regenerative med-
icine: the reviews and original articles in this special issue
highlight new methodological paradigms that challenge
current thinking in clinical research and boost the develop-
ment of clinical-grade MSCs under good manufacturing
practice protocols and conditions, an essential step towards
clinical applications.
The special issue has reported articles on MSCs used as
therapeutic aid in clinical and surgical applications. The
topics mainly reported have been the MSC therapy for spinal
cord injuries (A. Zadroga et al. and F. Salamanna et al.) and
the cell therapy as promising aid for retinal injuries due
to ischemic damage (L. Li et al.), as well as for the proper
management of stroke (C. Tan et al.).
The most reported translational use of MSC therapy is
related to bone tissue regeneration: in fact, many authors
have investigated about the osteogenic ability of different
stem cell types, with several scaffolds as support to regenera-
tion (Y. Kim et al.), as well as about the use of MSCs to treat
osteonecrosis in the maxillofacial region (T. Lombard et al.);
the dental-derived MSCs used for bone tissue engineering
seem to be still the most used by the S.I. authors (F. Posa
et al.), even if bone marrow cells have been used both in bone
regeneration (A. Scarano et al. and D. C. Bonfim et al.) and
also in the therapy of acute liver diseases (C. O. Kieling et al.).
A special attention has been paid also to umbilical cord
stem cells, due to their large application on translational
medicine (I. Arutyunyan et al.) and due to their ability to
produce exosomes with interesting abilities (B. Zhang et al.).
Some authors have focused their researches on the
influence of growth factors and proteins of ECM on MSCs
(A. Youssef et al. and M. Moslem et al.) as well as the
ability by MSCs to release GFs during their specific stage
of life (C. G. Pfeifer et al.) or in combination with
adipose-derived stem cells in bone regenerative protocols
(F. Mussano et al.).
An interesting general view has been also given on topics
related to MSCs of general interest, topics regarding the
innovative ways to manage and store the stem cells for
therapeutic uses in most different tissues (A. Bissoyi et al.
and R. Rohban and T. R. Pieber).
Finally, some authors have also reported interesting
aspects on regulatory and quality requirements in MSC
research (P. Galvez-Martin et al.).
In this special issue, the editors together with the involved
authors have well described the MSCs in their different but
fundamental roles as promoters, enhancers, and playmakers
of the translational regenerative medicine. Starting from the
contents of our issue, the scientific community will be stimu-
lated to experiment new ideas, to improve the knowledge of
the MSCs, and to speed up their clinical application, so to
improve the future therapies.
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